Skip to main content
OpenTrials
Completed

NCT Number: NCT01017731

Study of Ramucirumab (IMC-1121B) Therapy and Corrected QT (QTc) Interval Changes

The purpose of this study is to determine if Ramucirumab (IMC-1121B) causes prolongation of the QT/QTc interval in participants with advanced cancer.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Cancer Neoplasm Metastasis Neoplasms Neoplastic Processes Pathologic Processes Pathological Conditions, Signs and Symptoms Solid Tumor

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

ImClone Investigational Site, Atlanta, Georgia, United States

Loading trial locations.

About this study

The primary purpose of this study is to determine if treatment with ramucirumab causes prolongation of the QTc/QT interval in participants with advanced cancer, to assess the safety and tolerability of ramucirumab therapy, and to evaluate the pharmacokinetic (PK) characteristics of ramucirumab

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • The participant has histologically documented advanced or metastatic malignant cancer of solid tumor origin which has not responded to standard therapy or for which no standard therapy is available
  • The participant has resolution of adverse events from prior anticancer therapies
  • Performance status of 0 to 2
  • The participant is ≥ 18 years of age
  • The participant is able to provide informed written consent and is amenable to compliance with protocol schedules and testing
  • The participant has adequate liver, kidney, blood, and blood clotting functions as defined in trial entrance criteria
  • The participant agrees to use adequate contraception during the study period and for 8 weeks after the last dose of study treatment

Exclusion criteria

  • The participant had anticancer therapy within 14 days (6 weeks for nitrosoureas or mitomycin C) prior to entering the study
  • The participant had therapeutic radiotherapy within 14 days prior to entering the study
  • The participant has ongoing side effects ≥ Grade 2 due to prior anticancer therapy
  • The participant has brain or leptomeningeal metastases
  • The participant has a history of uncontrolled or severe cardiac disease
  • The participant has a history of severe congestive heart failure (CHF)
  • The participant has a known history of arterial thrombotic events
  • The participant has a known history of significant peripheral arterial disease (PAD)
  • The participant has an implantable pacemaker or automatic implantable cardioverter defibrillator (AICD)
  • The participant has a history of risk factors for ventricular tachycardia or Torsades de pointes (TdP) [for example, family history (parents or siblings) of long QT syndrome], history of fainting, unexplained loss of consciousness, or convulsions
  • The participant has a systolic blood pressure (SBP) of > 150 millimeters of mercury (mmHg) or < 90 mmHg or a diastolic blood pressure (DBP) of < 45 or > 95 mmHg. (Participants with a history of hypertension who are receiving antihypertensive therapy are permitted on study provided blood pressure is within the parameters detailed above)
  • The participant has a heart rate < 50 beats per minute (bpm) or > 100 bpm at rest
  • The participant has a clinically relevant abnormality on the ECG, preventing an accurate measurement of the QT interval
  • The participant is using a medication that is known to prolong the ECG QT interval
  • The participant has a known allergy to any of the treatment components including fluoroquinolone antibiotics
  • The participant has received an investigational new drug or device within 14 days prior to enrollment into this study (excluding placement of an intravenous access device)
  • The participant has undergone major surgery within 28 days prior to enrollment
  • The participant has known human immunodeficiency virus (HIV) infection
  • The participant, if female, is pregnant or lactating
  • The participant is receiving chronic daily treatment with aspirin [> 325 milligrams per day (mg/day)]
  • The participant has a concurrent active malignancy other than adequately treated nonmelanomatous skin cancer, other noninvasive carcinoma, or in situ neoplasm
  • The participant has psychological, familial, sociological, or geographical conditions which do not permit adequate study follow-up, compliance with the protocol, or signature of Informed Consent

Treatment and study plan

IMC-1121B

Biological

IMC-1121B (Ramucirumab) 10 mg/kg intravenously (IV) over 60 minutes, once every 3 weeks for minimum of 9 weeks.

Other names: Ramucirumab, LY3009806

moxifloxacin

Drug

Administered orally

diphenhydramine

Drug

Administered IV

Primary outcomes

  1. Change From Baseline to Cycle 3 in QT/Corrected QT (QTc) Interval Prolongation in Participants

    Time frame: Baseline, Cycle 3 (1 cycle=21 days)

    All electrocardiogram (ECG) tests were performed in triplicate prior to ramucirumab treatment. QT is the interval between the Q and T waves and QTc is the QT corrected for heart rate using Fridericia's formula: QTc = QT/RR^0.33 where RR is the interval between 2 R waves. Each participant's mean QT/QTc value was calculated for each ECG test during Cycle 3 and compared to his/her mean pretreatment QT/QTc value. The greatest change from baseline during Cycle 3 was reported. QTc prolongation is defined as a QTc exceeding 10 milliseconds (msec) with a lower 90% confidence interval (CI) exceeding 5 msec at any postdose time points per the International Conference on Harmonization (ICH) E14 guidelines for non-thorough QT studies (ICH 2005; ICH 2008). Least squares (LS) mean was calculated using a linear mixed model for repeated measures (MMRM) and adjusted for serum concentration.

Secondary outcomes

  1. Number of Participants With Drug-Related Adverse Events (AEs)

    Time frame: Baseline up to data cut off (approximately 105.6 weeks)

    Data presented are the number of participants who experienced treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), Grade 3 or higher TEAEs, or adverse events (AEs) leading to discontinuation of treatment that were considered to be related to ramucirumab. A summary of SAEs and other non-serious AEs, regardless of causality, is located in the Reported Adverse Events section.

  2. Maximum Concentration (Cmax) During Cycle 1

    Time frame: Cycle 1 [2.25 hours (h), 3.25 h, 4.25 h, 72 h, 168 h, 336 h postdose]

    Maximum observed concentration of IMC-1121B (ramucirumab) in serum during Cycle 1 (1 cycle=21 days).

  3. Maximum Concentration (Cmax) During Cycle 1, Day 4

    Time frame: Approximately Week 1 (Cycle 1, Day 4)

    Cmax was summarized once per cycle because participants only received 1 dose of IMC-1121B (ramucirumab) per cycle. Refer to secondary outcome measure 3 for Cmax during Cycle 1.

  4. Maximum Concentration (Cmax) During Cycle 1, Day 8

    Time frame: Approximately Week 2 (Cycle 1, Day 8)

    Cmax was summarized once per cycle because participants only received 1 dose of IMC-1121B (ramucirumab) per cycle. Refer to secondary outcome measure 3 for Cmax during Cycle 1.

  5. Maximum Concentration (Cmax) During Cycle 1, Day 15

    Time frame: Approximately Week 3 (Cycle 1, Day 15)

    Cmax was summarized once per cycle because participants only received 1 dose of IMC-1121B (ramucirumab) per cycle. Refer to secondary outcome measure 3 for Cmax during Cycle 1.

  6. Maximum Concentration (Cmax) During Cycle 2

    Time frame: Cycle 2 (predose and 1.25 hours postdose)

    Cmax was not calculated due to the sparse pharmacokinetic sampling employed on Cycle 2, Day 1.

  7. Maximum Concentration (Cmax) During Cycle 3

    Time frame: Cycle 3 [predose and 1.25 hours (h), 2.25 h, 3.25 h, 4.25 h, 72 h, 168 h, 336 h, and 504 h postdose]

    The maximum observed serum concentration of IMC-1121B (ramucirumab) at steady state (Cmax,ss) during Cycle 3 (1 cycle=21 days).

  8. Area Under Concentration (AUC) During Cycle 1

    Time frame: Cycle 1 [2.25 hours (h), 3.25 h, 4.25 h, 72 h, 168 h, 336 h postdose]

    The area under the concentration versus time curve from time 0 to infinity [AUC(0-inf)] is reported during Cycle 1 (1 cycle=21 days).

  9. Area Under Concentration (AUC) During Cycle 1, Day 4

    Time frame: Approximately Week 1 (Cycle 1, Day 4)

    AUC was summarized once per cycle because participants only received 1 dose of IMC-1121B (ramucirumab) per cycle. Refer to secondary outcome measure 9 for AUC during Cycle 1 (Day 1 through Day 15).

  10. Area Under Concentration (AUC) During Cycle 1, Day 8

    Time frame: Approximately Week 2 (Cycle 1, Day 8)

    AUC was summarized once per cycle because participants only received 1 dose of IMC-1121B (ramucirumab) per cycle. Refer to secondary outcome measure 9 for AUC during Cycle 1 (Day 1 through Day 15).

  11. Area Under Concentration (AUC) During Cycle 1, Day 15

    Time frame: Approximately Week 3 (Cycle 1, Day 15)

    AUC was summarized once per cycle because participants only received 1 dose of IMC-1121B (ramucirumab) per cycle. Refer to secondary outcome measure 9 for AUC during Cycle 1 (Day 1 through Day 15).

  12. Area Under Concentration (AUC) During Cycle 2, Day 1

    Time frame: Approximately Week 1 (Cycle 2, Day 1)

    AUC was not calculated due to the sparse pharmacokinetic sampling employed on Cycle 2, Day 1.

  13. Area Under Concentration (AUC) During Cycle 3

    Time frame: Cycle 3 [predose and 1.25 hours (h), 2.25 h, 3.25 h, 4.25 h, 72 h, 168 h, 336 h, and 504 h postdose]

    The area under the concentration versus time curve over the dosing interval at steady state [AUC(tau,ss)] is reported during Cycle 3 (1 cycle=21 days).

Sponsors and collaborators

Lead sponsor

Eli Lilly and Company

Industry

Registry information

Official study title

A Study to Evaluate the Relationship Between Ramucirumab (IMC-1121B) Therapy and Corrected QT (QTc) Interval Changes in Patients With Advanced Cancer

Important dates

Study start
2009
Primary completion
2010
Study completion
2014
First posted
Nov 23, 2009
Registry last updated
Jun 10, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.